# Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

> **NCT00086658** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 86 (actual)

## Conditions studied

- Hypereosinophilia
- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** mepolizumab

## Key facts

- **NCT ID:** NCT00086658
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-23
- **Primary completion:** 2006-05-01
- **Final completion:** 2006-05-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2020-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086658, "Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00086658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*